Zungur Mustafa, Gul Ilker, Tastan Ahmet, Damar Ertan, Tavli Talat
Department of Cardiology, Sifa University Faculty of Medicine, Izmir, Turkey.
Department of Anesthesiology and Reanimation, Sifa University Faculty of Medicine, Izmir, Turkey.
Cardiorenal Med. 2016 Aug;6(4):279-88. doi: 10.1159/000443936. Epub 2016 May 5.
BACKGROUND/AIMS: The Mehran risk score (MS) was adopted to predict the development of contrast-induced nephropathy (CIN) and includes clinical and procedural variables. In this study, we aimed to evaluate the value of MS in the prediction of CIN development after transcatheter aortic valve implantation (TAVI).
Ninety-three patients (47 females; mean age, 77.2 ± 7.6 years) who underwent aortic valve replacement with TAVI for severe aortic stenosis in our center between June 2013 and November 2014 were included in the study. Patients were categorized into four risk groups based on MS: low (≤5), moderate (6-10), high (11-15), and very high (≥16).
CIN was recorded in 24 patients after TAVI (25.8%). The amount of contrast medium was significantly higher in the CIN+ group (p = 0.029), and total mortality was higher in the CIN+ group than in the CIN- group (20.1 vs. 2.9%, respectively; p = 0.024). In univariate analysis, diabetes mellitus, coronary artery disease, ejection fraction, baseline creatinine, baseline glomerular filtration rate, contrast medium volume, and MS were found to be significant risk factors for CIN (p < 0.05 for all). The receiver operating characteristic analysis of the significant variables in multivariate regression analysis revealed that the cutoff MS to predict the development of CIN was 13.0 (area under the curve, 0.654; 95% confidence interval, 0.495-0.758; sensitivity, 62%; specificity, 68%).
MS is a predictor of CIN development after TAVI. We think that the use of MS in clinical practice may decrease renal complications after TAVI.
背景/目的:梅兰风险评分(MS)用于预测对比剂肾病(CIN)的发生,包括临床和手术变量。在本研究中,我们旨在评估MS在经导管主动脉瓣植入术(TAVI)后预测CIN发生的价值。
纳入2013年6月至2014年11月在我们中心接受TAVI治疗严重主动脉瓣狭窄的93例患者(47例女性;平均年龄77.2±7.6岁)。根据MS将患者分为四个风险组:低(≤5)、中(6 - 10)、高(11 - 15)和极高(≥16)。
TAVI术后24例患者(25.8%)出现CIN。CIN+组的造影剂用量显著更高(p = 0.029),CIN+组的总死亡率高于CIN-组(分别为20.1%和2.9%;p = 0.024)。单因素分析发现,糖尿病、冠状动脉疾病、射血分数、基线肌酐、基线肾小球滤过率、造影剂用量和MS是CIN的显著危险因素(所有p < 0.05)。多因素回归分析中显著变量的受试者工作特征分析显示,预测CIN发生的MS临界值为13.0(曲线下面积,0.654;95%置信区间,0.495 - 0.758;敏感性,62%;特异性,68%)。
MS是TAVI后CIN发生的预测指标。我们认为在临床实践中使用MS可能会降低TAVI后的肾脏并发症。